PRESS RELEASE
April 20, 2007
Agel is pleased to announce that renowned scientist Dr. Ann de Wees Allen, Chief of
Biomedical Research at the Glycemic Research Institute, has joined the Agel Team.
Dr. Allen and Agel Enterprises will be introducing products that incorporate Dr. Allen’s Larginine patents and Agel’s cutting edge “Suspension Gel Technology”.
Dr. Allen has been researching and patenting safe forms of L-arginine since 1983, and
currently has the only technology for creating Blind Amino Acid Riders for L-arginine. Dr.
Allen also received the first glycemic patent ever awarded worldwide.
Agel began operations in 2005 and has announced business operations in 43 countries.
“Our Suspension Gel Technology combined with Dr. Allen’s products will open a whole
new vista of opportunity for Agel Team Members globally”, said Glen Jensen, Agel CEO
and founder.
Because this opportunity has presented itself so quickly, Agel has not had time to
develop a product that combines Dr. Allen’s patented L-arginine and Agel’s suspension
gel. For this reason, Agel will begin offering Dr. Allen’s L-arginine as a powder in order to
fill present product demand while it develops a gel based product to replace the powder.
Once the gel based product is finished development, it will be available to team
members worldwide.
Dr. Allen stated, “I am thrilled to be working with Agel. Together, we will make a real
difference in the field of nutrition and anti-aging.”
Dr. Allen will also serve as Head of the Medical Advisory Board at Agel.
A list of Dr. Allen’s Bio and patents can be seen at:
www.AnndeWeesAllen.com
www.GlycemicResearchLaboratories.com
Information on how you can be part of the Agel team is available at www.agel.com or by contacting us at AgelTN@gmail.com.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment